{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:29:15Z","timestamp":1776086955005,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and\/or divergent differentiation (SH\/DD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective analysis of 113 UC samples with SH\/DD at our institution from 2011 to 2021. Immunohistochemical staining for Trop-2 and ephrin B2 expression was performed on all cases. Expression was determined by the percentage of samples with a moderate or strong H-score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Our results show Trop-2 expression was the highest in squamous cell carcinoma and UC with squamous differentiation, adenocarcinoma and UC with glandular differentiation, and plasmacytoid subtype, while ephrin B2 expression was highest in adenocarcinoma, UC with glandular differentiation, and small cell carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Expression of Trop-2 and ephrin B2 may demonstrate therapeutic possibilities for patients with SH\/DD, who usually have limited treatment options, particularly in small cell carcinoma, in which few targets have been identified. Clinical trials to investigate the efficacy of these novel treatments are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqae161","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T19:24:01Z","timestamp":1734722641000},"page":"618-628","source":"Crossref","is-referenced-by-count":5,"title":["Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes"],"prefix":"10.1093","volume":"163","author":[{"given":"Katherine B","family":"Case","sequence":"first","affiliation":[{"name":"Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan J","family":"Martini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Massachusetts General Hospital , Boston, MA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melad N","family":"Dababneh","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, University of Alabama at Birmingham , Birmingham, AL ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bidot","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, MA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-1329","authenticated-orcid":false,"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine , Atlanta, GA ,","place":["US"]},{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine , Atlanta, GA ,","place":["US"]},{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreyas","family":"Joshi","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]},{"name":"Department of Urology, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Narayan","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]},{"name":"Department of Urology, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaunita","family":"Parihar","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Saeed","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]},{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine , Atlanta, GA ,","place":["US"]},{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara R","family":"Harik","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University , Atlanta, GA ,","place":["US"]},{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, GA ,","place":["US"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"1","key":"2025042104184555100_CIT0001","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"2025042104184555100_CIT0002"},{"issue":"1","key":"2025042104184555100_CIT0003","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2025042104184555100_CIT0004","doi-asserted-by":"publisher","first-page":"32","DOI":"10.32074\/1591-951X-838","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"115","author":"Raspollini","year":"2022","journal-title":"Pathologica."},{"key":"2025042104184555100_CIT0005","volume-title":"Invasive Urothelial Carcinoma: Subtypes and Divergent Differentiation","author":"Downes","year":"2022"},{"issue":"6","key":"2025042104184555100_CIT0006","first-page":"900","article-title":"Treatment patterns and survival outcomes for patients with small cell carcinoma of the bladder","volume":"4","author":"Fischer-Valuck","year":"2018","journal-title":"Bladder Cancer"},{"issue":"4","key":"2025042104184555100_CIT0007","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/JU.0000000000002799","article-title":"Survival impact of variant histology diagnosis in upper tract urothelial carcinoma","volume":"208","author":"Nogueira","year":"2022","journal-title":"J Urol."},{"issue":"10","key":"2025042104184555100_CIT0008","doi-asserted-by":"publisher","first-page":"6565","DOI":"10.21037\/tcr-20-2169","article-title":"Variant histology in bladder cancer: diagnostic and clinical implications","volume":"9","author":"Black","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"5","key":"2025042104184555100_CIT0009","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.21873\/invivo.12968","article-title":"Squamous or glandular differentiation predicts poor prognosis in pT1 urothelial carcinoma","volume":"36","author":"Nakagawa","year":"2022","journal-title":"In Vivo"},{"issue":"12","key":"2025042104184555100_CIT0010","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s11255-022-03358-3","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter","volume":"54","author":"Catarino","year":"2022","journal-title":"Int Urol Nephrol."},{"issue":"6","key":"2025042104184555100_CIT0011","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.juro.2007.08.038","article-title":"Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder","volume":"178","author":"Wright","year":"2007","journal-title":"J Urol."},{"issue":"1","key":"2025042104184555100_CIT0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulous LNK","year":"2020","journal-title":"Bladder Cancer"},{"issue":"1","key":"2025042104184555100_CIT0013","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/PAS.0000000000002077","article-title":"International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas","volume":"48","author":"Paner","year":"2024","journal-title":"Am J Surg Pathol."},{"issue":"22","key":"2025042104184555100_CIT0014","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol."},{"issue":"29","key":"2025042104184555100_CIT0015","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025042104184555100_CIT0016","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-020-0879-y","article-title":"Antibody-drug conjugates in urothelial carcinomas","volume":"22","author":"Sarfaty","year":"2020","journal-title":"Curr Oncol Rep."},{"issue":"19","key":"2025042104184555100_CIT0017","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.3390\/ijms21197268","article-title":"Targeted molecular therapeutics for bladder cancer\u2014a new option beyond the mixed fortunes of immune checkpoint inhibitors","volume":"21","author":"Bednova","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"4","key":"2025042104184555100_CIT0018","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737140.2022.2049763","article-title":"Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma","volume":"22","author":"Mathew Thomas","year":"2022","journal-title":"Expert Rev Anticancer Ther."},{"issue":"1","key":"2025042104184555100_CIT0019","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","article-title":"Sacituzumab govitecan, a novel antibody\u2013drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma","volume":"14","author":"Faltas","year":"2016","journal-title":"Clin Genitourin Cancer."},{"issue":"35","key":"2025042104184555100_CIT0020","doi-asserted-by":"publisher","first-page":"58642","DOI":"10.18632\/oncotarget.17407","article-title":"The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer","volume":"8","author":"Avellini","year":"2017","journal-title":"Oncotarget"},{"key":"2025042104184555100_CIT0021","doi-asserted-by":"publisher","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci Rep."},{"issue":"8","key":"2025042104184555100_CIT0022","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/ajhp\/zxab464","article-title":"The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer","volume":"79","author":"Hanna","year":"2022","journal-title":"Am J Health Syst Pharm."},{"key":"2025042104184555100_CIT0023","volume-title":"FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer","year":"2021"},{"issue":"1","key":"2025042104184555100_CIT0024","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","article-title":"Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan","volume":"10","author":"Zeybek","year":"2020","journal-title":"Sci Rep."},{"issue":"3","key":"2025042104184555100_CIT0025","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol Oncol."},{"issue":"8","key":"2025042104184555100_CIT0026","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3349\/ymj.2021.62.8.679","article-title":"Low expression of EphB2, EphB3, and EphB4 in bladder cancer: novel potential indicators of muscular invasion","volume":"62","author":"Lee","year":"2021","journal-title":"Yonsei Med J."},{"issue":"3","key":"2025042104184555100_CIT0027","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"2025042104184555100_CIT0028","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/mc.22574","article-title":"Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors","volume":"56","author":"Oweida","year":"2017","journal-title":"Mol Carcinog."},{"issue":"8","key":"2025042104184555100_CIT0029","doi-asserted-by":"publisher","first-page":"e105326","DOI":"10.1371\/journal.pone.0105326","article-title":"The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One."},{"key":"2025042104184555100_CIT0030","year":"2024"},{"issue":"1","key":"2025042104184555100_CIT0031","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"2025042104184555100_CIT0032","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2011"},{"issue":"4","key":"2025042104184555100_CIT0033","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol."},{"issue":"8","key":"2025042104184555100_CIT0034","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol."},{"issue":"10","key":"2025042104184555100_CIT0035","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"2025042104184555100_CIT0036","volume-title":"Study of sacituzumab govitecan versus physician\u2019s choice of treatment in participants with urothelial cancer that cannot be removed or has spread (TROPiCS-04). NCT04527991","author":"Gilead Sciences"},{"issue":"6","key":"2025042104184555100_CIT0037","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/curroncol29060312","article-title":"Trop-2 in upper tract urothelial carcinoma","volume":"29","author":"Tomiyama","year":"2022","journal-title":"Curr Oncol."},{"issue":"6","key":"2025042104184555100_CIT0038","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/ol.2023.14114","article-title":"Immunohistochemical expression of Trop-2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer","volume":"26","author":"Abbas","year":"2023","journal-title":"Oncol Lett"},{"issue":"1","key":"2025042104184555100_CIT0039","first-page":"1643","article-title":"Trop2 is associated with the recurrence of patients with non-muscle invasive bladder cancer","volume":"10","author":"Zhang","year":"2017","journal-title":"Int J Clin Exp Med."},{"key":"2025042104184555100_CIT0040","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/OTT.S339348","article-title":"Targeted therapy for locally advanced or metastatic urothelial cancer (mUC): therapeutic potential of sacituzumab govitecan","volume":"15","author":"Fontes","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"21","key":"2025042104184555100_CIT0041","doi-asserted-by":"publisher","first-page":"11547","DOI":"10.3390\/ijms222111547","article-title":"Evaluation of therapeutic targets in histological subtypes of bladder cancer","volume":"22","author":"Wucherpfennig","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2025042104184555100_CIT0042","doi-asserted-by":"publisher","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, Trop-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"2025042104184555100_CIT0043","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2025042104184555100_CIT0044","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.clgc.2023.05.014","article-title":"Metastatic bladder cancer expression and subcellular localization of nectin-4 and Trop-2 in variant histology: a rapid autopsy study","volume":"21","author":"Ghali","year":"2023","journal-title":"Clin Genitourin Cancer."},{"issue":"1","key":"2025042104184555100_CIT0045","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2025042104184555100_CIT0046","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1200\/JCO.21.02923","article-title":"EphrinB2 inhibition and pembrolizumab in metastatic urothelial carcinoma","volume":"41","author":"Sadeghi","year":"2023","journal-title":"J Clin Oncol."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/4\/618\/61249483\/aqae161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/4\/618\/61249483\/aqae161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:19:03Z","timestamp":1745223543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/163\/4\/618\/7929838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2025,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqae161","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,20]]}}}